Bartholin's gland cancer is a rare vulvar cancer that starts in the small glands near the vaginal opening. People with Bartholin's gland cancer may notice a firm lump, pain with sitting or sex, bleeding, or swelling that does not go away. It mainly affects adults, most often after menopause, and symptoms can build slowly over months. Treatment usually includes surgery and may add radiation or chemotherapy, and recovery depends on stage and cell type. The outlook varies, but many people do well when Bartholin's gland cancer is found and treated early.
Overview
Bartholin's gland cancerSymptoms
Bartholin's gland cancer often shows up as a firm lump near the vaginal opening that doesn’t go away, sometimes with pain, swelling, or bleeding. Early symptoms of Bartholin's gland cancer can include discomfort with sitting or sex and groin swelling.
Outlook and prognosis
Many living with Bartholin's gland cancer do well when it’s found early and treated by a gynecologic oncology team. Prognosis depends on tumor stage, type, and lymph node involvement. Regular follow-up helps spot recurrences early and manage long-term side effects.
Causes and risk factors
The exact cause of Bartholin's gland cancer is often unknown. Risk rises with age (especially over 40), high-risk HPV infection, smoking, and immune suppression. Prior vulvar precancer or cancer may also increase risk.
Genetic influences
Genetics play a limited role in Bartholin's gland cancer; most cases are not inherited. Rarely, changes in tumor genes like TP53 or PIK3CA are found in the cancer cells, not passed down. Family cancer syndromes are uncommon here.
Diagnosis
Doctors start with a pelvic exam and history. A persistent or unusual Bartholin’s mass is sampled with a biopsy to confirm cancer. MRI or CT scans, and sometimes lymph node checks, help stage Bartholin’s gland cancer.
Treatment and drugs
Treatment for Bartholin’s gland cancer usually combines surgery to remove the tumor with targeted radiation, and sometimes chemotherapy. Care teams may also use lymph node evaluation and reconstructive techniques to support comfort, sexual function, and bladder or bowel control. Regular follow-up helps catch recurrence early.
Symptoms
Bartholin's gland cancer often shows up as a firm, one-sided lump near the vaginal opening, sometimes making sitting, walking, or sex uncomfortable. Early on, this might look like a simple Bartholin cyst or abscess that keeps coming back or doesn’t improve with usual care. Early symptoms of Bartholin's gland cancer can be subtle—like a persistent lump, swelling, or new bleeding—so it’s worth getting any lasting change checked.
A firm or hard lump on one side of the vaginal opening can occur with Bartholin's gland cancer. It may start small and feel like a pea or marble under the skin.
A lump that seems like a Bartholin cyst but keeps returning or doesn’t improve after treatment can be a warning sign. This is especially important to mention if new or persistent after age 40.
Aching, sharp pain, or a feeling of pressure near the vaginal opening can occur. It may worsen when sitting, walking, cycling, or during sex.
The area on one side of the vulva may look swollen or feel heavy. Tight clothing or long sitting can make the fullness more noticeable.
How people usually first notice Bartholin's gland cancer?
Many first notice Bartholin’s gland cancer as a firm, painless or only slightly tender lump near the vaginal opening that doesn’t go away, especially if it seems fixed in place rather than soft like a typical cyst. Over weeks to months, the area may become uncomfortable during sitting, walking, or sex, and some notice bleeding, a sore that doesn’t heal, or swelling of nearby groin lymph nodes. While most Bartholin’s gland swellings are benign cysts or infections, persistent or recurrent lumps after age 40 are a key “first signs of Bartholin’s gland cancer” cue to seek prompt evaluation.
Types of Bartholin's gland cancer
Bartholin's gland cancer is rare, and doctors generally group it by the kind of cells involved and how far it has spread. This helps explain why symptoms can vary—from a painless lump near the vaginal opening to soreness, bleeding, or trouble sitting or walking. Clinicians often describe them in these categories: the main tumor cell type, whether it stays in place or invades nearby tissue, whether it has reached lymph nodes, and whether it has spread to distant sites. Knowing the types of Bartholin's gland cancer can also clarify treatment options and outlook.
Squamous cell
This is the most common type and starts in the flat surface cells of the vulvar area around the gland. People may notice a firm lump, soreness, or skin changes near the Bartholin’s gland.
Adenocarcinoma
This type grows from the gland’s mucus-producing cells. It may feel like a deepening mass in the gland area and can cause pain or discharge.
Adenoid cystic
This uncommon type tends to grow slowly but can track along nerves, causing burning or aching pain. It may return years later even after treatment.
Melanoma
This rare variant can arise from pigment cells near the gland. People may see a dark spot or patch with irregular edges, sometimes with itching or bleeding.
Paget-associated
In some, gland cancer occurs with extramammary Paget disease of the vulva. This can present with red, itchy, eczema-like skin plus an underlying gland tumor.
In situ lesions
These are very early, surface-limited changes without invasion into deeper tissue. Early symptoms of Bartholin's gland cancer at this stage may be mild or absent.
Localized invasive
The tumor has grown into nearby gland or vulvar tissue but has not reached lymph nodes. Symptoms often include a persistent lump, discomfort, or pain with sitting or sex.
Node-positive
Cancer cells have spread to nearby groin (inguinal) lymph nodes. People may feel groin lumps or fullness along with the primary gland mass.
Metastatic
Cancer has spread to distant organs such as lungs or liver. Fatigue, weight loss, or cough may appear alongside local vulvar symptoms.
What genetics can tell you about symptoms
Some people with inherited changes in tumor-suppressor genes like BRCA1/BRCA2 have higher risk for vulvar cancers, which can include rare Bartholin’s gland tumors. When these genes don’t repair DNA well, symptoms may include a persistent vulvar lump, pain, or bleeding.
Causes and risk factors
Bartholin's gland cancer begins when cells in the gland change and grow out of control.
Having risk factors doesn’t mean you’ll definitely develop the condition.
Because it is rare, risk factors for Bartholin's gland cancer are not fully defined.
Risk seems higher with older age, especially after menopause, and with long-term infection with human papillomavirus (HPV).
Smoking and a weak immune system can raise risk, while inherited causes are uncommon.
Environmental and biological risk factors
Bartholin's gland cancer is rare, and risk tends to come from a mix of body-based factors and outside exposures. Doctors often group risks into internal (biological) and external (environmental). Below are environmental and biological risk factors for Bartholin's gland cancer that clinicians watch for. Having one or more does not mean you will develop it.
Risk increases with age, and most cases are diagnosed after menopause. Age-related tissue changes can make abnormal cell growth more likely. This pattern is seen across vulvar cancers, including Bartholin's gland cancer.
Infection with high-risk human papillomavirus (HPV) can trigger precancerous changes in the vulvar region. This exposure is most strongly tied to the squamous cell subtype of Bartholin's gland cancer. Plenty of people with similar exposures live without developing the condition.
A weakened immune system makes it harder to clear HPV and repair damaged cells. Immune suppression from conditions like HIV or from long-term anti-rejection medicines raises the chance of cancers in this area, including Bartholin's gland cancer.
Past precancerous changes of the cervix, vagina, or vulva point to persistent high-risk HPV activity. This background can spill over to nearby structures and slightly increase risk for Bartholin's gland cancer.
Genetic risk factors
Most cases of Bartholin's gland cancer are not inherited. The main genetic risk factors for Bartholin's gland cancer are not clearly defined because it’s very rare. Carrying a genetic change doesn’t guarantee the condition will appear. Doctors usually focus on DNA changes found in the tumor itself, and consider rare inherited syndromes only when family history is strong.
Mostly not inherited: Most Bartholin's gland cancers arise without an inherited gene change. They develop from DNA changes that build up in gland cells over time.
Family history clues: There is no clear pattern tying family history to higher risk for this cancer. If several close relatives had gynecologic cancers at young ages, a genetics visit may be advised to look for a shared inherited cause.
Rare inherited syndromes: Some inherited DNA-repair conditions, such as Lynch syndrome, raise risks for certain gynecologic cancers. A direct link to Bartholin's gland cancer is unproven, but these syndromes are considered when family history is strong.
Somatic DNA changes: In most cases, the tumor carries acquired DNA changes (not inherited) that drive cell growth. These changes are present only in the cancer and are not passed to children. Testing the tumor can sometimes detect these changes.
BRCA genes not linked: BRCA1 and BRCA2 increase risks for breast and ovarian cancer. They are not known to raise the risk of Bartholin's gland cancer. People with BRCA changes generally do not need extra checks specifically for this cancer.
Research gaps: Because this cancer is very rare, studies on inherited risk are limited. Current evidence suggests no single gene explains most cases.
Lifestyle risk factors
Evidence on lifestyle risk factors for Bartholin's gland cancer is limited due to its rarity, but patterns seen in vulvar cancers provide guidance. Behaviors that increase exposure to high-risk HPV and those that impair local immune defenses appear most relevant. The following focuses on lifestyle risk factors for Bartholin's gland cancer and how everyday choices may influence risk or delay diagnosis.
Multiple partners and inconsistent condom use increase exposure to high-risk HPV types linked to vulvar and some Bartholin’s gland cancers. Safer sex practices may reduce HPV transmission and persistent infection.
Smoking weakens local immune defenses and helps HPV persist in vulvar tissues, which raises squamous cell cancer risk in the area. Quitting smoking may lower carcinogenic changes in the vulvar/Bartholin region.
Recurrent cysts, abscesses, or irritation near the Bartholin area may promote long-term inflammation, which can support cancerous changes over time. Prompt treatment of infections and minimizing irritants may reduce this inflammatory burden.
Excess body weight and low physical activity contribute to systemic inflammation and hormonal changes that can promote gynecologic cancers in general. Weight management and regular movement may indirectly reduce carcinogenic pressures around the vulva/Bartholin gland.
Risk prevention
Bartholin's gland cancer is rare, and there’s no sure way to prevent it, but you can lower risk and catch problems sooner. Some steps target HPV, a virus linked to certain vulvar cancers, while others focus on reducing irritation and staying alert to changes. Screenings and check-ups are part of prevention too. If something doesn’t feel normal for you, it’s worth getting it checked.
Getting the HPV vaccine lowers the chance of HPV-related vulvar cancers, which may include some Bartholin’s gland cancers. It works best when given before sexual activity but can still help many adults.
Using condoms or dental dams can reduce HPV and other STIs that may raise cancer risk over time. Limiting the number of partners also lowers exposure.
Smoking is linked to vulvar cancer, so stopping can reduce risk over time. Ask about nicotine replacement, prescriptions, or support programs if you need help.
Routine gynecologic visits can spot changes near the Bartholin gland early. This is especially important if you’ve had a persistent lump or recurring “cyst.”
Transmission
Bartholin's gland cancer is not contagious, so it can’t be caught or spread through touch, sharing towels, kissing, or sex. If you’re worried about how Bartholin's gland cancer is transmitted, it isn’t; having a partner with this cancer doesn’t put you at risk, and it is not passed to a baby during pregnancy or breastfeeding. While certain infections such as HPV can raise the risk for some vulvar cancers, the cancer itself is not an infection and cannot be transmitted person to person. Bartholin's gland cancer also usually does not run in families; most cases happen because of genetic changes that build up in the gland’s cells over time, not because of inherited genes.
When to test your genes
Consider genetic testing if you were diagnosed with Bartholin’s gland cancer at a young age, have rare or aggressive histology, or there’s a strong family history of ovarian, breast, pancreatic, prostate, or colon cancers. Testing can uncover inherited risks (like BRCA1/2 or Lynch) that guide surgery, screening, and targeted therapies. A genetics professional can help choose the right test and interpret results.
Diagnosis
Bartholin's gland cancer often comes to light when a firm lump, pressure, or pain near the vaginal opening makes sitting, cycling, or sex uncomfortable. For many, the first step comes when everyday activities start feeling harder. Doctors usually begin with a focused exam and then use tests to confirm the cause and see how far it has spread. Understanding how Bartholin's gland cancer is diagnosed can help you know what to expect and why each step matters.
Your clinician asks about symptoms like a persistent lump, pain, bleeding, discharge, or changes over time. They’ll note age, prior Bartholin cysts or infections, and any treatments that didn’t help.
Doctors may perform a careful vulvar and internal exam to locate the lump and check surrounding tissues. They look for features that suggest a solid mass versus a simple cyst or abscess.
A small sample of the lump is removed with a punch or excisional biopsy. Pathology confirms the diagnosis of Bartholin's gland cancer and identifies the tumor type to guide treatment.
An ultrasound can help distinguish a fluid-filled cyst from a solid or mixed mass. This quick imaging test can guide whether immediate drainage is reasonable or a biopsy is needed.
Stages of Bartholin's gland cancer
Doctors stage Bartholin's gland cancer using the same system used for vulvar cancers, which helps guide treatment and outlook. Different tests may be suggested to help assess how far the cancer has spread, including pelvic exam, imaging, and sometimes sentinel lymph node biopsy. Early symptoms of Bartholin's gland cancer can be subtle, so staging relies more on exam, biopsy, and scans than on symptoms.
Stage I
Bartholin’s gland cancer is limited to the gland area and nearby vulvar skin. No spread to lymph nodes or nearby organs.
Stage II
The cancer has grown into nearby areas such as the lower vagina, lower urethra, or anus. Lymph nodes are not involved.
Stage III
The cancer may be any size and has spread to groin (inguinal-femoral) lymph nodes. Nearby structures may or may not also be involved.
Stage IV
Bartholin’s gland cancer has reached the upper urethra or upper vagina, bladder, rectum, pelvic bone, or distant organs. Lymph nodes can be fixed or ulcerated in more advanced disease.
Outlook and prognosis
Looking ahead can feel daunting, but most people want a clear sense of what comes next with Bartholin's gland cancer. Outcomes vary because this is a rare vulvar cancer, and it’s often found later since early symptoms of Bartholin's gland cancer can mimic a simple cyst or abscess. When the tumor is caught early and fully removed, long-term control is possible, especially when surgery is combined with targeted radiation. If lymph nodes in the groin are involved, treatment is more intensive and the chance of the cancer returning is higher, but modern care plans aim to lower that risk.
Prognosis refers to how a condition tends to change or stabilize over time. For Bartholin's gland cancer, stage at diagnosis, lymph node status, and whether surgeons can get clear margins are the biggest drivers of outlook. Some people experience no further issues after initial treatment, while others notice local recurrences within the first few years, which is why close follow-up is key. If the cancer spreads to distant sites, survival drops, but newer systemic therapies used for vulvar cancers in general are expanding options.
Everyone’s journey looks a little different. Reported five‑year survival ranges widely—from good in early, node‑negative disease to more limited when nodes or distant organs are involved. Most recurrences happen within two to three years, so regular exams and imaging during that window matter. Talk with your doctor about what your personal outlook might look like, including how your pathology, lymph node findings, and overall health shape next steps.
Long-term effects
For many, the lasting impact comes from both the cancer and the treatments used around the vulva and groin. Long-term effects vary widely, and depend on tumor stage, lymph node involvement, and the extent of surgery or radiation. Many are first evaluated for what seems like a stubborn “cyst,” and early symptoms of Bartholin's gland cancer can be subtle—this sometimes influences the long-term picture. Over time, daily routines may shift to account for changes in comfort, sensation, and intimacy.
Bartholin's gland cancer can come back locally in the vulva or in nearby lymph nodes. The chance depends on the original stage and margins from surgery. Recurrence can happen months or years later.
If cancer cells reach groin nodes, long-term outlook is generally more guarded. This can raise the risk of future spread to distant sites.
Removal or radiation of groin nodes can lead to long-term leg or vulvar swelling. Swelling may fluctuate but can become persistent over time.
Pain, tightness, numbness, or dryness can affect arousal and comfort with intercourse. Scarring and reduced elasticity around the vaginal opening may make penetration difficult.
How is it to live with Bartholin's gland cancer?
Living with Bartholin’s gland cancer often means navigating intimate discomfort, changes in sexual health, and the practical demands of treatment, from surgery or radiation appointments to healing time and follow-up exams. Many notice pain, swelling, or tenderness in the vulvar area that can affect sitting, walking, exercise, and intimacy; pelvic floor discomfort and dryness may make sexual activity challenging, and counseling plus gentle rehabilitation can help. Partners, family, and close friends often become part of the care team—rides to visits, help with daily tasks, and patient listening matter—and clear communication can reduce anxiety for everyone. With a coordinated plan from gynecologic oncology, pain control, and supportive care, many regain comfort and find a new normal that respects both health and intimacy.
Treatment and drugs
Bartholin's gland cancer is rare, so treatment is usually planned by a specialist team based on the tumor’s size, whether it has spread, and your overall health. Surgery is the main treatment; many people have removal of the tumor with a margin of healthy tissue, and some need wider surgery that may include nearby lymph nodes in the groin to check for spread. Radiation therapy may be used before surgery to shrink the tumor or after surgery to lower the risk of it coming back, and it can also help control symptoms if surgery isn’t possible. Chemotherapy is less commonly used but may be combined with radiation or used for cancer that has spread; a doctor may adjust your dose to balance benefits and side effects. Supportive care can make a real difference in how you feel day to day, including pain control, wound care after surgery, pelvic floor therapy, sexual health support, and counseling.
Non-drug treatment
Treatments that don’t rely on medicines for Bartholin's gland cancer include surgery, radiation, and supportive therapies that help with healing and quality of life. Alongside medicines, non-drug therapies often lay the foundation for comfort, function, and recovery during and after care. Plans are tailored to the tumor’s stage, your goals, and any other health needs. If you first sought care because of early symptoms of Bartholin's gland cancer, these approaches can also ease lingering pain, swelling, or intimacy concerns.
Removal of the tumor and a margin of nearby tissue is often recommended. This is the main way to remove Bartholin's gland cancer in the vulvar area.
Carefully targeted beams can be used after surgery or when surgery isn’t possible. It can shrink or control Bartholin's gland cancer and relieve pain or bleeding.
A small dye-guided procedure checks the first lymph nodes that drain the vulva. Results help stage Bartholin's gland cancer while lowering the risk of leg swelling compared with full node removal.
Specialist-guided exercises, relaxation, and gentle manual techniques improve pelvic comfort and function. This can ease pain, muscle tightness, and urinary changes after treatment.
Your genes may have an impact on how drugs work for you
Two people can receive the same drug for Bartholin’s gland cancer yet respond differently because genes shape how fast the body activates, breaks down, or clears medicines. Genetic differences may affect side effects, effective dose, and eligibility for targeted therapies.
Pharmacological treatments
Medicines for Bartholin's gland cancer are usually used alongside surgery and radiation, especially if the cancer has spread or comes back. Because early symptoms of Bartholin's gland cancer can look like a simple cyst, drug therapy is often considered after the diagnosis is confirmed and staging is complete. Not everyone responds to the same medication in the same way. Doctors choose drugs based on the tumor type (squamous vs adenocarcinoma), spread, and your overall health.
Cisplatin is often given weekly with radiation to make the radiation work better. This approach is common for squamous-type tumors or when lymph nodes are involved. Side effects can include nausea, fatigue, and temporary kidney strain, so hydration and monitoring are important.
This two-drug chemotherapy is widely used for advanced or recurrent disease, especially for adenocarcinoma patterns. It can shrink tumors and help control symptoms. Hair loss, low blood counts, and numbness or tingling in fingers and toes can occur.
Cisplatin combined with 5‑fluorouracil (5‑FU) is another option, used either with radiation or as systemic chemotherapy. It may be chosen when taxanes are not suitable. Mouth sores and low blood counts are the most common side effects.
This PD‑1 blocker may be used for tumors that are PD‑L1 positive, mismatch‑repair deficient (dMMR)/MSI‑H, or have high tumor mutational burden. It helps the immune system recognize and attack cancer cells. Side effects can include fatigue and, rarely, immune‑related inflammation of organs that needs prompt care.
Genetic influences
Most cases of Bartholin's gland cancer do not run in families, and a clear inherited cause hasn’t been identified. Genetics is only one piece of the puzzle, but doctors do find gene changes inside the tumor that arise over time (somatic changes) and can drive its growth. These changes are not passed from parent to child, which is why a family history of Bartholin's gland cancer is uncommon. Because of this, genetic testing for Bartholin's gland cancer most often looks at the tumor itself to see whether certain changes could guide treatment; testing of your inherited DNA is considered when your personal or family history points to a broader hereditary cancer risk. If your family has several relatives with cancers such as breast, ovarian, uterine, or colorectal cancer—especially at younger ages—your team may discuss genetic counseling in addition to standard care. Your individual risk will be guided by your own history and the tumor’s features rather than family history alone.
Is Bartholin's gland cancer genetic?
Genetics play a limited role in Bartholin's gland cancer; most cases are not inherited. Rarely, changes in tumor genes like TP53 or PIK3CA are found in the cancer cells, not passed down. Family cancer syndromes are uncommon here.
Pharmacogenetics—how genetics influence drug effects
Because Bartholin's gland cancer is rare, doctors often use genetic information to fine‑tune treatment rather than rely on a one‑size‑fits‑all plan. Alongside your medical history and other test results, genetic testing can help tailor chemotherapy choices or doses.
If a regimen includes 5‑fluorouracil (often called 5‑FU) or capecitabine, many centers check for changes in a gene called DPYD; people with certain results may need a lower dose to lower the risk of severe side effects, or a different drug. Tumor profiling may also look for features such as mismatch repair deficiency (sometimes reported as dMMR) or an NTRK fusion—findings that can open the door to approved immunotherapy or targeted treatments used across many solid cancers. Genes are only part of the picture, so your team will combine these results with pathology, imaging, and how you’re feeling to make Bartholin's gland cancer care safer and more precise.
Interactions with other conditions
Day to day, other health issues can shape how Bartholin's gland cancer is found and treated. Doctors call it a “comorbidity” when two conditions occur together. Long-standing Bartholin cysts or repeated infections in the same area can mask early symptoms of Bartholin's gland cancer, so new firmness, pain, or a lump that doesn’t settle should be checked even if similar problems happened before. Infections such as HPV may play a role in some vulvar cancers, and immune system conditions like HIV or medicines that suppress immunity can raise infection risk and slow healing after surgery or radiation. Diabetes can also affect wound healing and make post‑procedure infections more likely, and blood thinners may increase bleeding with biopsies or operations. When other vulvar skin conditions are present, soreness or itching can blur the picture, making it harder to tell what is causing which symptom, so coordinated care with your gynecologist and any other specialists is helpful.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described painful swellings near the vaginal opening, often treated as cysts or abscesses long before anyone imagined a hidden tumor. In many communities, a “Bartholin’s cyst” that kept coming back was drained repeatedly at home or in clinics, because that was the familiar explanation. Only when a lump felt unusually firm, fixed, or ulcerated—and didn’t settle after typical care—did doctors start to consider Bartholin’s gland cancer.
First described in the medical literature as a very uncommon vulvar tumor, Bartholin’s gland cancer was initially recognized mostly through surgical case reports. Early on, it was often misclassified, because infections of the Bartholin’s gland are common while cancer there is rare. From these first observations, surgeons and pathologists began to separate persistent, hard masses from routine cysts, and to note patterns like spread to nearby lymph nodes in the groin.
As medical science evolved, microscopists refined how these cancers were grouped by cell type, which helped guide treatment choices. Before imaging was widely available, diagnosis relied on careful examination and biopsy. Over time, descriptions became more precise: a lump in the Bartholin’s area that recurred after drainage, appeared in people after menopause, or caused bleeding or pain during sex raised more concern and led to earlier sampling rather than repeat drainage.
In recent decades, knowledge has built on a long tradition of observation. Better pathology tools, including immunostaining, clarified whether a tumor started in the gland or arrived from nearby tissue. Imaging such as ultrasound and MRI helped define size and local spread before surgery. Multidisciplinary care brought together gynecology, oncology, and radiation therapy, moving management from single, extensive operations toward tailored combinations of surgery, lymph node assessment, and, when needed, radiation or chemotherapy.
Despite evolving definitions, the central lesson has held: any new or persistent Bartholin’s area mass, especially in people over 40 to 50, deserves evaluation and often a biopsy. This shift from “drain first” to “sample if suspicious” changed outcomes by finding Bartholin’s gland cancer earlier. Today, registries and collaborative studies continue to refine staging and treatment, but the historical arc is clear—what began as scattered case reports has become a structured approach that distinguishes routine gland problems from a rare cancer that needs prompt, specialized care.